Standard BioTools Inc. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Standard BioTools Inc. (LAB) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $176.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-08.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2022-03-08
- Standard BioTools Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2020-09-30 was $180.00K.
- Standard BioTools Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2020 was $176.00K.
- Standard BioTools Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2012 was $3.97M.
- Standard BioTools Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2010 was $66.00K.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|---|
| 2020-12-31 | $176.00K 10-K · filed 2022-03-08 | |
| 2020-09-30 | $180.00K 10-Q · filed 2021-11-09 | |
| 2012-12-31 | $3.97M 10-K · filed 2015-02-26 | |
| 2010-12-31 | $66.00K 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |